1031435-50-3

Basic information

• Product Name: 1-bromobenzyl-3-[3-tert-butylsulfanyl-5-(methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid ethyl ester
• Synonyms: 1-bromobenzyl-3-[3-tert-butylsulfanyl-5-(methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid ethyl ester
• CAS NO: 1031435-50-3
• Molecular Weight: 532.542
• Mol File: 1031435-50-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 618.2±55.0 °C(Predicted)
• Density: 1.22±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 1-bromobenzyl-3-[3-tert-butylsulfanyl-5-(methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bromobenzyl-3-[3-tert-butylsulfanyl-5-(methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid ethyl ester(1031435-50-3)
• EPA Substance Registry System: 1-bromobenzyl-3-[3-tert-butylsulfanyl-5-(methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid ethyl ester(1031435-50-3)

Safety Data

• Hazardous Substances Data: 1031435-50-3(Hazardous Substances Data)

Upstream product

• 136558-13-9 ethyl 5-t-butylthio-2,2-dimethyl-4-oxo-pentanoate 
• 176045-80-0 N-(4-bromobenzyl)-N-(4-methoxyphenyl)-hydrazine 

Downstream Products

• 936351-54-1 3-[1-(4-bromo-benzyl)-3-tert-butylsulfanyl-5-hydroxy-1H-indol-2-yl]-2,2-dimethyl-propionic acid ethyl ester 

Relevant articles and documents

5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert- Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2- ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643) - A potent FLAP inhibitor suitable for topical administration

AM643 (compound 6, 3-{3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)- benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid) was identified as a potential candidate for formulation as a topical agent for the treatment of skin disorders involving leukotriene production. Dermal application of 6 using a prototypical vehicle in a murine ear arachidonic acid model showed significant reduction in the concentrations of leukotrienes in mouse skin with concomitant reduction in ear swelling.

5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITOR

Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates the

COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS

Disclosed herein are compositions and compounds that combine an inhibitor of 5-lipoxygenase activating protein (FLAP) and a modulator of NO levels in a mammal. The NO modulator can be an agent that induces the production of NO in a mammal, or can be an ag